Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announces financial and operating results for the first quarter ended March 31, 2020. Company improved financial and operating results are reflected in every major financial category, as compared to first quarter […]
Author: Ken Dropiewski
Neovasc Announces $11.5 Million Registered Direct Offering Priced At-The-Market
Vancouver, BC, June 12, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE –Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 3,883,036 common shares at a purchase price of […]
LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S. subsidiary, LivaNova USA, Inc., in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, […]
Radcliffe Cardiology Announces New Educational Hub, Arrhythmia Academy
LONDON, June 10, 2020 /PRNewswire/ — An exciting new digital platform – ‘Arrhythmia Academy’ launches today – dedicated to arrhythmia and electrophysiology specialists. This new scientific content hub is led by Editor-in-Chief Prof Angelo Auricchio, MD, PhD, (Lugano, Switzerland) and is supported by a stellar, international editorial board. In association with leading Cardiovascular content provider Radcliffe […]
Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease
Proceeds Will Be Used to Progress Lead Program to Phase 1 Clinical Trials and Expand Pipeline Programs CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it has raised $63 […]
Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk
Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS–(BUSINESS WIRE)–Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today […]
Cardiovascular Systems Prices Public Offering of Common Stock
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the pricing of its previously announced underwritten public offering of 3,676,471 shares of its common stock at a price to […]
MIVI Neuroscience Announces FDA IDE Clinical Study Approval For the MIVI Q Aspiration Catheter
EDEN PRAIRIE, Minn., June 9, 2020 /PRNewswire/ — MIVI Neuroscience, a leading developer, and marketer of precision stroke therapy devices utilized by neurointerventionists around the world, announced today that the FDA has determined the company has provided sufficient data to support initiation of a human clinical study of the MIVI Q Aspiration Catheter […]
CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting
The presentation was selected as Top Bioengineering Abstract and confirms CorWave’s commitment to scientific excellence, which enabled demonstration of its Left Ventricular Assist Device’s (LVAD) capability to provide durable, long-term circulatory support with high-fidelity physiologic flow CLICHY, France–(BUSINESS WIRE)–CorWave announced today that the latest results of its preclinical Left Ventricular […]
Reflow Medical Enrolls First Patients in the DEEPER LIMUS Study of the Temporary Spur Stent System
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc., a California-based medical device company, has enrolled the first patients in A Non-RanDomized Pilot Study of the TEmporary Spur StEnt System for the Treatment of Lesions Located in the InfraPoplitEal ARteries Using a LIMUS-base Drug-coated Balloon (DEEPER LIMUS). The OUS single center clinical trial […]



